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Background: Pyronaridine-artesunate (PA) is indicated for the treatment of acute uncomplicated Plasmodium
falciparum and Plasmodium vivax malaria.
Methods: Individual patient data on safety outcomes were integrated from six randomized clinical trials conducted
in Africa and Asia in patients with microscopically confirmed P. falciparum (five studies) or P. vivax (one study)
malaria. Efficacy against P. falciparum was evaluated across three Phase III clinical trials.
Results: The safety population included 2,815 patients randomized to PA, 1,254 to comparators: mefloquine +
artesunate (MQ + AS), artemether-lumefantrine (AL), or chloroquine. All treatments were generally well tolerated.
Adverse events occurred in 57.2% (1,611/2,815) of patients with PA versus 51.5% (646/1,254) for comparators, most
commonly (PA; comparators): headache (10.6%; 9.9%), cough (5.9%; 5.6%) and anaemia (4.5%; 2.9%). Serious averse
events were uncommon for all treatments (0–0.7%). Transient increases in alanine aminotransferase and aspartate
aminotransferase were observed with PA but did not lead to any clinical sequelae. For P. falciparum malaria, day-28
PCR-corrected adequate clinical and parasitological response with PA was 93.6% ([1,921/2,052] 95% CI 92.6, 94.7) in
the intent-to-treat population and 98.5% ([1,852/1,880] 95% CI 98.0, 99.1) in the per-protocol population. Median
parasite clearance time was 24.1 h with PA, 31.9 h with MQ + AS, and 24.0 h with AL. Median fever clearance time
was 15.5 h with PA, 15.8 h with MQ + AS, and 14.0 h with AL. By day 42, P. falciparum gametocytes had declined to
near zero for all treatments.
Conclusions: Pyronaridine-artesunate was well tolerated with no safety concerns with the exception of mostly mild
transient rises in transaminases. Efficacy was high and met the requirements for use as first-line therapy.
Pyronaridine-artesunate should be considered for inclusion in malaria treatment programmes.
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More than three billion people are at risk of malaria [1].
Despite recent progress in malaria control, there were
around 216 million episodes of clinical infection in 2010
[1]. Most malaria deaths, around 655,000 each year,
occur from Plasmodium falciparum infection in children
under five years of age [1,2]. However, the important
contribution of Plasmodium vivax infection to global
malaria morbidity is now also being recognized [3-6].
For P. falciparum malaria, artemisinin-based combi-
nation therapy (ACT) is generally recommended by the
World Heath Organization (WHO) [7]. Parasite burden
and fever are rapidly reduced with ACT and efficacy
remains high in most regions [7]. Artemisinin tolerance –
observed as extended parasite clearance times with ACT
treatment – has emerged among P. falciparum from the
Cambodia–Thailand border areas [8-15], with some
evidence of resistance spreading at the Thailand–Myanmar
border [16]. For P. vivax, the WHO recommends ACT in
areas where chloroquine resistance has emerged [7]; most
notably Indonesia, though there are also reports from
further east in the Malay archipelago to Papua New Guinea
and Vietnam as well as from South America and Oceania
[17,18]. Using ACT in areas co-endemic for P. falciparum
and P. vivax has also been suggested as a strategy to
overcome difficulties in differential diagnosis and in cases
of mixed infection [17,19,20].
Pyronaridine-artesunate (PA) (3:1 ratio) is a novel ACT
indicated for the treatment of acute uncomplicated P.
falciparum or P. vivax malaria [15,21-25]. In vitro studies
indicate potent activity against recent isolates of multidrug-
resistant strains of both P. falciparum and P. vivax from
Papua, Indonesia [26], against Kenyan P. falciparum
isolates [27], and against around half of chloroquine-
resistant P. falciparum strains from the China–Myanmar
border area [28]. The PA clinical development programme
included two Phase II trials and three Phase III trials in
children and adults from Africa and Asia with uncompli-
cated P. falciparum malaria [15,22,24,25], as well as one
comparative Phase III trial in children and adults with un-
complicated P. vivax infection [23]. The programme
incorporated parallel development of an adult tablet and a
paediatric granule formulation [22], shown in a Phase II
study to display similar bioavailability [24]. In all four Phase
III studies, PA efficacy was non-inferior to the comparator
anti-malarial drugs and PA was generally well tolerated
[15,22,23,25].
The objective of this paper was to evaluate PA safety
outcomes by integrating individual patient data from
two Phase II and four Phase III randomized clinical trials
[15,22-25]. Efficacy outcomes for PA in uncomplicated
P. falciparum malaria were examined descriptively
across the three Phase III trials that included patients
with this infection [15,22,25].Methods
Ethics statement
The clinical trials were conducted in accordance with
the Declaration of Helsinki (Tokyo 2004), Good Clinical
Practice and applicable regulations. Trial protocols were
approved by the independent ethics committee of each
study centre. All patients or their guardians provided
informed written or witnessed oral consent; assent was
required from children able to understand the study.
Source data
Individual patient data were integrated from six PA
randomized clinical trials, two Phase II studies and four
Phase III studies, conducted in sub-Saharan Africa,
Southeast Asia and India between 2005 and 2008
(Table 1) [15,22-25]. Further details of the trial protocols
are supplied in the published reports [15,22-25].
Details of the studies included in this analysis are
summarized in Table 1. The two Phase II studies were
non-comparative; one was a dose escalation study to
examine the safety and pharmacokinetics of the PA tablet
and granule formulations in children with P. falciparum
(SP-C-003-05) [24], the other was a dose ranging study
(SP-C-002-05) of PA tablets in adults with P. falciparum
malaria. Of the four Phase III studies, three were
conducted in subjects with P. falciparum [15,22,25], two
studies used PA tablets [15,25], and one the PA granule
formulation [22]. The remaining Phase III study included
subjects with P. vivax malaria [23]. All four Phase III
studies were non-inferiority studies against comparators
recommended as first-line anti-malarial therapy in the
relevant countries. The non-inferiority margin was 5% in
the two P. falciparum tablet studies that included both
children and adults (SP-C-004-06, SP-C-005-06), and 10%
in the paediatric granule P. falciparum study (SP-C-007-07)
and the P. vivax study (SP-C-006-06).
Treatments
Pyronaridine-artesunate (Shin Poong Pharmaceutical
Company Ltd, Ansan, South Korea) was supplied as
tablets (180:60 mg per tablet) or as a paediatric granule
formulation presented in sachets (60:20 mg per sachet).
In the Phase III studies, PA was given once daily for
three days (day 0, 1, 2), dosed by body weight as follows,
for tablets: 20–25 kg one tablet, 26–44 kg two tablets,
45–64 kg three tablets, 65–90 kg four tablets, i e, 7.2:2.4
to 13.8:4.6 mg/kg/dose; and for granules, ≥5– <9 kg one
sachet, 9– <17 kg two sachets, 17– <25 kg three sachets,
i e, 6.7:2.2 to 13.3:4.4 mg/kg/dose.
The comparators in the PA Phase III P. falciparum stud-
ies were dosed by body weight. Artemether-lumefantrine
(AL) was given twice daily for three days, at 0.9:5.3 to
2.4:14.4 mg/kg/dose for tablets in SP-C-005-06 and 1.3:8.0
to 4.0:24.0 mg/kg/dose for crushed tablets in SP-C-007-07.
Table 1 Summary of pyronaridine-artesunate Phase II/III randomized clinical trials included in the integrated analysis
Protocol SP-C-002-05 SP-C-003-05 [24] SP-C-004-06 [15] SP-C-005-06 [25] SP-C-007-07 [22] SP-C-006-06 [23]
Phase II II III III III III
Region/country SE Asia, Africa Gabon SE Asia, India, Africa Africa, SE Asia Africa, SE Asia SE Asia, India
Year 2005–2006 2006 2007–2008 2007–2008 2007–2008 2007–2008
Design DB/MC/DF OL/DF OL/MC/CM DB/DD/MC/CM OL/MC/CM DB/DD/MC/CM
Pathogen P. falciparum P. falciparum P. falciparum P. falciparum P. falciparum P. vivax
Parasite counta, μL-1 1000–100,000 1000–200,000 1000–100,000 1000–100,000 1000–200,000 ≥250
Patient age, years 15–60 2–14 3–60 3–60 ≤12 3–60
Patient weight, kg 35–75 10–40 20–90 20–90 ≥5– <25 20–90
PA target doseb, mg/kg/day 6:2, 9:3, 12:4 6:2, 9:3, 12:4 Granule: 9:3 7.2:2.4–13.8:4.6 7.2:2.4–13.8:4.6 6.7:2.2–13.3:4.4 7.2:2.4–13.8:4.6
PA dose form Tablet Tablet and granule Tablet Tablet Granule Tablet
Comparator – – MQ+ AS AL ALb CQ
Study design: CM, comparative; DB, double-blind; DD, double-dummy; DF, dose-finding; MC, multi-centre; OL, open label.
Comparators: MQ + AS, mefloquine plus artesunate; AL, artemether-lumefantrine; CQ, chloroquine.
a Asexual parasite count for P. falciparum and including at least 50% asexual parasites for P. vivax.
b Crushed tablets.
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practices. Mefloquine + artesunate (MQ+AS) was given
as a loose combination, once daily for three days at 5.6:2.2
to 12.5:5.0 mg/kg/dose in study SP-C-004-06. In the Phase
III P. vivax study (SP-C-006-06), the comparator chloro-
quine (CQ) was given once daily for three days at a daily
dose in children of 10 mg/kg on days 0 and 1 and 5 mg/kg
on day 2 and for adults of 620 mg on days 0 and 1 and
310 mg on day 2.
Patients and procedures
Patients and procedures are described in detail else-
where [15,22-25]. In brief, patients of either gender were
eligible if they had P. falciparum mono-infection, or in
SP-C-006-06 P. vivax mono-infection, in all cases
microscopically confirmed within defined limits
(Table 1), with fever or a history of fever while
meeting age/body weight criteria for each study
(Table 1). Patients were excluded if they had signifi-
cant co-morbid illness, recent anti-malarial therapy,
known hypersensitivity to study drugs, evidence of
severe malnutrition, if they were pregnant (test
required) or breastfeeding, or had participated previously
in a PA clinical trial.
At screening, a medical history was taken and a phy-
sical examination performed. All enrolled patients were
hospitalized from day 0 to 3. Follow-up assessments
were at days 7, 14, 21, 28, 35 and 42. Vital signs and
malaria signs/symptoms were monitored throughout the
study. Temperature was taken at screening, every 8 h
over ≥72 h following the first dose or until two normal
readings between 7 and 25 h apart, then at each visit or
as clinically indicated. Venous blood samples were taken
for clinical biochemistry, haematology and urinalysis
testing and 12-lead electrocardiographs were performedat screening and then at intervals as specified in the
protocol.
Parasitological assessments were performed according
to WHO guidelines [29]. Giemsa-stained thick blood
slides were prepared before each dose, every 8 h (±1 h)
following first dose administration for ≥72 h or until
parasite clearance (two consecutive negative readings 7 to
25 h apart), and at subsequent visits. For P. falciparum,
asexual and gametocyte parasite counts were performed
separately; for P. vivax asexual and gametocyte parasite
counts were recorded separately at screening and total
parasite counts recorded at all other assessments. Thin
blood slides were prepared for parasite identification at
screening and from day 7 at all follow-up visits. In
the P. falciparum Phase III studies, recrudescence was
determined by PCR genotyping using P. falciparum
genes msp 1, msp 2, and glurp; defined as at least
one matching allelic band in all markers between
baseline and post-day-7 samples [30,31].
Outcomes
Safety outcomes were adverse event incidence and severity
(categorized using MedDRA version 10.1), laboratory
abnormalities (graded according to the Division of
Microbiology and Infectious Diseases Toxicity Scale),
and electrocardiograph abnormalities.
Efficacy outcomes were integrated for the Phase III P.
falciparum studies only and were defined according to
WHO methods [29]. The primary efficacy outcome was
day-28 PCR-corrected adequate clinical and parasitological
response (ACPR), defined as clearance of asexual parasit-
aemia without recrudescence or previous treatment failure.
Day-28 uncorrected ACPR was a secondary endpoint.
Secondary efficacy endpoints were parasite clearance
time (time from first dose to asexual aparasitaemia for
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clearance time (time from first dose to apyrexia for two
consecutive normal temperature readings 7–25 h apart);
and the proportion of subjects aparasitic and proportion
apyretic at day 1 (24 h after the first dose), day 2 (48 h
after the first dose), and day 3 (72 h after the first dose).
The proportion of patients with gametocytes at each
assessment was an exploratory endpoint.
Statistical methods
The safety analysis included data from all Phase II
and Phase III studies and was conducted on the
safety population, i e, all patients who had received
any amount of study drug. Descriptive statistics were
provided for safety outcomes.
The efficacy analysis included data from the Phase
III P. falciparum trials and in the integrated analysis
was conducted primarily on the intent-to-treat (ITT)
population, i e, all randomized patients with P. falciparum
malaria who received any amount of study medication.
This definition was consistent across all the Phase III
P. falciparum studies. Descriptive statistics were
provided for efficacy outcomes.
Descriptive sub-group analyses were performed for
day-28 PCR-corrected ACPR for the ITT population as
follows: region (Asia, Africa); age (<5, 5–12, >12– <18,
≥18 years); gender (male, female); weight (<17, ≥17–
<25, ≥25 kg); previous malaria episode (yes, no); number
of previous malaria episodes in the last 12 months (0, 1,
>1); baseline parasitaemia (≤5,000, >5,000–10,000,
>10,000 μL-1); PA formulation (granule, tablet); and PA
actual dose (≤8.5:2.8, >8.5:2.8–9.5:3.2, >9.5:3.2–11.0:3.7,
>11.0:3.7 mg/kg/day).Table 2 Subject disposition
Subjects PA safety PA efficacy (ITT) MQ + A
Treatedb 2815 2052
Completed treatmentc 2773 (98.5) 2017 (98.3)
Completed study 2410 (85.6) 1748 (85.2)
Discontinued: 405 (14.4) 304 (14.8)
Adverse event 46 (1.6) 32 (1.6)
Consent withdrawn 26 (0.9) 19 (0.9)
Insufficient therapeutic effect 11 (0.4) 0
Lost to follow-up 99 (3.5) 69 (3.4)
Protocol violation 9 (0.3) 4 (0.2)
Malaria infection 186 (6.6) 174 (8.5)
Other 28 (1.0) 6 (0.3)
Data are n (%).
PA, pyronaridine-artesunate; MQ + AS, mefloquine plus artesunate; AL, artemether-l
a For comparators, MQ + AS, AL and CQ were included in the safety analysis; MQ + A
b Received at least one dose of study medication.
c Received all planned doses of study medication.Post-hoc analyses of time to recrudescence and time
to re-infection conducted using Kaplan-Meier estimates
(log-rank test) were conducted for the integrated ana-
lysis; subjects without the event were censored at the
last available parasite assessment date.
Kaplan-Meier estimates were used to evaluate parasite
clearance time and fever clearance time. Subjects
without parasite or fever clearance within 72 h after the first
treatment dose were censored at that time point. An
additional analysis of parasite clearance time in Cambodia
(Pailin at the Cambodia–Thailand border) versus Thailand
(Mae Sot and Mae Ramat) was performed without
censoring at 72 h. The proportion of subjects with
parasite clearance and the proportion of subjects with
fever clearance on days 1, 2 and 3 were calculated
using Kaplan-Meier estimates. Log10 area under the
curve (AUC) for gametocyte density was calculated in
count · day/μL based on a log10 transformation. Statistical
analysis was performed using SAS (Version 9.1).
Results
Patients
Overall, 2,817 patients were randomized to PA and
1,254 to comparators (MQ +AS, AL and CQ). Two
subjects did not receive PA and were excluded from the
safety population (n = 2,815) (Table 2). A similar propor-
tion of patients in the PA group (14.4% [405/2,815])
discontinued treatment as for comparators (17.6% [221/
1,254]). In the efficacy (ITT) population, 2,052 subjects
with P. falciparum malaria were treated with PA and
1,026 with comparators (MQ + AS or AL) (Table 2).
Subject disposition for the efficacy ITT population
was similar to that of the safety population (Table 2).S safety/efficacy AL safety/efficacy CQ safety All comparators
safetya
423 603 228 1254
418 (98.8) 587 (97.3) 220 (96.5) 1225 (97.7)
357 (84.4) 489 (81.1) 187 (82.0) 1033 (82.4)
66 (15.6) 114 (18.9) 41 (18.0) 221 (17.6)
4 (0.9) 10 (1.7) 2 (0.9) 16 (1.3)
6 (1.4) 11 (1.8) 5 (2.2) 22 (1.8)
0 0 0 0
25 (5.9) 10 (1.7) 12 (5.3) 47 (3.7)
0 1 (0.2) 0 1 (0.1)
29 (6.9) 78 (12.9) 21 (9.2) 128 (10.2)
2 (0.5) 4 (0.7) 1 (0.4) 7 (0.6)
umefantrine; CQ, chloroquine.
S and AL in the efficacy analysis.
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of patients were treated for P. falciparum and 8.1% (228/
2,815) for P. vivax malaria, 49.3% (1,389/2,815) of subjects
were from Asia, 50.7% (1,426/2,815) from Africa and mean
patient age was 20.6 years (Table 3). Overall in the safety
population, the PA group and the combined comparators
group were well balanced for baseline demographic and
clinical characteristics (Table 3). However, for individual
comparators, integration of the data led to imbalances
in patient age and the regions from which patients
were recruited because of the different study entry
criteria (Table 3).
Safety
In the safety population, medication was taken as
planned for 98.9% (2,785/2,815) of patients receiving PATable 3 Patient baseline characteristics
Characteristic PA safetya PA efficacy (ITT)a M
n = 2815 n = 2052
Female gender, n (%) 956 (34.0) 751 (36.6)




Age category, years, n (%)
≤1 year 9 (0.3) 9 (0.4)
>1– <5 173 (6.1) 150 (7.3)
5–12 704 (25.0) 656 (32.0)
>12– <18 401 (14.2) 316 (15.4)
≥18 1528 (54.3) 921 (44.9)
Region, n (%)b
Africa 1426 (50.7) 1223 (59.6)
Asia 1389 (49.3) 829 (40.4)




Malaria in last 12 months, n (%) n = 2551 n = 2045
0 1431 (56.1) 1064 (52.0)
1 498 (19.5) 444 (21.7)
>1 622 (24.4) 537 (26.3)
P. falciparum parasitaemia,
μL-1, n (%)c
≤5000 691 (26.8) 521 (25.4)
>5000–10,000 394 (15.3) 293 (14.3)
>10,000 1497 (58.0) 1238 (60.3)





Mean haemoglobin, g/dL (SD) 11.9 (2.0) 11.8 (2.0)
PA, pyronaridine-artesunate; MQ + AS, mefloquine plus artesunate; AL, artemether-l
a The safety analysis included data from all Phase II and Phase III studies. The effica
comparators, MQ + AS, AL and CQ were included in the safety analysis; MQ + AS an
b All subjects from African centres were of Black ethnicity except one in the AL gro
Asian/Oriental ethnicity.
c Baseline P. falciparum parasite count was not available for five patients in the PAand 98.6% (1,236/1,254) of those receiving comparators.
All drug treatments were generally well tolerated. The
number of patients with at least one treatment-emergent
adverse event was similar for PA (57.2% [1,611/2,815])
and comparators (51.5% [646/1,254]), as was the number
of patients thought to have adverse events related to
drug therapy: 25.2% (708/2,815) and 25.5% (320/1,254),
respectively. The nature and incidence of adverse events
due to any cause was similar for PA versus combined
comparators (Table 4). The most common adverse
events were headache (10.6% PA; 9.9% comparators),
cough (5.9% PA; 5.6% comparators) and anaemia (4.5%
PA; 2.9% comparators) (Table 4).
Serious adverse events occurred in 0.6% (18/2,815) of
patients in the PA group and in 0.4% (5/1,254) in the
combined comparators. There were no deaths. OneQ + AS safety/
efficacy
AL safety/efficacy CQ safety All comparators
safetya
n = 423 n = 603 n =228 n = 1254









0 3 (0.5) 0 3 (0.2)
0 68 (11.3) 0 68 (5.4)
61 (14.4) 274 (45.4) 9 (3.9) 344 (27.4)
53 (12.5) 92 (15.3) 28 (12.3) 173 (13.8)
309 (73.0) 166 (27.5) 191 (83.8) 666 (53.1)
79 (18.7) 531 (88.1) 0 610 (48.6)









n = 423 n = 600 n = 228 n = 1251
258 (61.0) 269 (44.8) 123 (53.9) 650 (52.0)
92 (21.7) 116 (19.3) 58 (25.4) 266 (21.3)
73 (17.3) 215 (35.8) 47 (20.6) 335 (26.8)
113 (26.7) 161 (26.7) – 274 (26.7)
72 (17.0) 81 (13.5) – 153 (14.9)




12.1 (2.0) 11.5 (1.9) 12.3 (1.8) 11.9 (1.9)
umefantrine; CQ, chloroquine.
cy analysis included data from the Phase III P. falciparum trials. For
d AL in the efficacy analysis.
up who was Asian/Oriental; all patients from Asian centres were of
group and one patient in the AL group.
Table 4 Treatment-emergent adverse events of any cause occurring in ≥2% of all subjects in any treatment group
(safety population)
Adverse event PA MQ + AS AL CQ All comparators
(n = 2815) (n = 423) (n = 603) (n = 228) (n = 1254)
Any adverse event 1611 (57.2) 190 (44.9) 384 (63.7) 72 (31.6) 646 (51.5)
Blood and lymphatic system disorders
Anaemia 128 (4.5) 17 (4.0) 18 (3.0) 1 (0.4) 36 (2.9)
Basophilia 9 (0.3) 9 (2.1) 1 (0.2) 0 10 (0.8)
Eosinophilia 101 (3.6) 5 (1.2) 27 (4.5) 4 (1.8) 36 (2.9)
Lymphocytosis 21 (0.7) 0 16 (2.7) 0 16 (1.3)
Neutropenia 55 (2.0) 0 27 (4.5) 0 27 (2.2)
Gastrointestinal disorders
Abdominal pain 98 (3.5) 7 (1.7) 31 (5.1) 2 (0.9) 40 (3.2)
Diarrhoea 41 (1.5) 9 (2.1) 6 (1.0) 2 (0.9) 17 (1.4)
Vomiting 124 (4.4) 9 (2.1) 23 (3.8) 7 (3.1) 39 (3.1)
General disorders
Fatigue 49 (1.7) 6 (1.4) 3 (0.5) 11 (4.8) 20 (1.6)
Influenza-like illness 49 (1.7) 0 21 (3.5) 0 21 (1.7)
Pyrexia 66 (2.3) 4 (0.9) 18 (3.0) 2 (0.9) 24 (1.9)
Infections and infestations
Bronchitis 52 (1.8) 6 (1.4) 12 (2.0) 3 (1.3) 21 (1.7)
Nasopharyngitis 74 (2.6) 11 (2.6) 8 (1.3) 6 (2.6) 25 (2.0)
Rhinitis 19 (0.7) 2 (0.5) 12 (2.0) 0 14 (1.1)
Upper RTI 100 (3.6) 4 (0.9) 31 (5.1) 0 35 (2.8)
Urinary tract infection 34 (1.2) 3 (0.7) 12 (2.0) 1 (0.4) 16 (1.3)
Investigations
AST increased 63 (2.2) 1 (0.2) 14 (2.3) 0 15 (1.2)
Blood albumin decreased 21 (0.7) 0 16 (2.7) 0 16 (1.3)
Blood CPK increased 26 (0.9) 4 (0.9) 3 (0.5) 8 (3.5) 15 (1.2)
Blood glucose decreased 33 (1.2) 0 19 (3.2) 0 19 (1.5)
ECG QT prolongation 6 (0.2) 5 (1.2) 1 (0.2) 6 (2.6) 12 (1.0)
Eosinophil count increased 58 (2.1) 6 (1.4) 2 (0.3) 0 8 (0.6)
Platelet count increased 59 (2.1) 3 (0.7) 20 (3.3) 0 23 (1.8)
Metabolism and nutrition disorders
Anorexia 85 (3.0) 13 (3.1) 10 (1.7) 10 (4.4) 33 (2.6)
Musculoskeletal and connective tissue disorders
Myalgia 107 (3.8) 19 (4.5) 1 (0.2) 21 (9.2) 41 (3.3)
Nervous system disorders
Dizziness 39 (1.4) 28 (6.6) 1 (0.2) 6 (2.6) 35 (2.8)
Headache 297 (10.6) 44 (10.4) 46 (7.6) 34 (14.9) 124 (9.9)
Respiratory, thoracic and mediastinal disorders
Cough 167 (5.9) 10 (2.4) 55 (9.1) 5 (2.2) 70 (5.6)
Data are n (%). PA, pyronaridine-artesunate; MQ + AS, mefloquine plus artesunate; AL, artemether-lumefantrine; CQ, chloroquine; RTI, respiratory tract infection;
AST aspartate aminotransferase; CPK, creatine phosphokinase; ECG, electrocardiograph.
Values underlined are for adverse events occurring in ≥2% of patients in one group versus any other group.
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Figure 1 Changes from baseline in haematology parameters in
patients receiving pyronaridine-artesunate or combined
comparators (safety population). NB: Day-28 values are available
for the Plasmodium vivax study only [23].
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that were considered treatment-related (hepatic enzyme
increased and abortion incomplete) and one patient receiv-
ing MQ+AS had two treatment-related serious adverse
events (convulsion and grand mal convulsion). All other
serious adverse events were considered not to be related to
treatment: in the PA group there were two cases each of
pyrexia, malaria, typhoid fever and urinary tract infection,
and one case each of anaemia, cardiac failure, abdominal
pain, limb abscess, cholera, paronychia, parotitis, pneumo-
nia, acute pyelonephritis, wound infection, abortion
complete and depression; for comparators there were two
cases of cerebral malaria and one of immunosuppression.
Overall, adverse events leading to study withdrawal
occurred in 1.6% (44/2,815) of patients in the PA group
and 1.0% (13/1,254) in the comparator group; vomiting
was the reason in 1.1% (32/2,815) and 0.9% (11/1,254) of
cases, respectively. In the PA group, other reasons for
study withdrawal were P. falciparum infection (0.3%; 9/
2,815), malaria (0.1%; 3/2,815) and one case each of
nausea and fatigue. In the comparator group there were
two cases of cerebral malaria (0.2%) leading to study
withdrawal. Of the patients who were withdrawn from
the study because of an adverse event, drug treatment
was discontinued in 2.2% (27/1,254) of patients in the
PA group (26 instances of vomiting, one of nausea, one
of malaria) and in 1.0% (12/1,254) of patients receiving
comparators (10 vomiting, two cerebral malaria).
There were no major differences between PA and
comparators in haematology parameters over the course
of the study (Figure 1). For all treatment groups, there
was a small decrease in haemoglobin concentration on
day 3 (mean <1 g/dL) with recovery to baseline levels by
day 28, and corresponding changes in haematocrit and
red blood cells. Proportional decreases in neutrophils
from baseline were associated with mean proportional
increases in lymphocytes and eosinophils. Platelet counts
were low at baseline and had increased by day 7 in all
treatment groups. There were no clinically meaningful
changes from baseline for white blood cells, monocytes
or basophils in any treatment group.
No clinically important changes from baseline were
observed in total bilirubin, alkaline phosphatase, creatinine,
albumin, creatine kinase, urea, sodium, potassium, glucose
or blood urea nitrogen in any treatment group. In the PA
group, both alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were increased on day 3 and day 7
versus baseline, and normalized by day 28 (Figure 2). In the
PA group, treatment-emergent Grade 3/4 toxicities for
ALT were recorded for 0.4% (11/2,750) of patients on day
3 and 0.9% (24/2,709) on day 7; for AST the incidence was
0.5% (13/2,757) and 0.3% (9/2,711), respectively. For
comparators, in the MQ+AS group 0.2% (1/404) of
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Day 28
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Values are means (± standard deviation) 








–11.37 –11.37 –11.42 –12.10 –11.12–11.66
Figure 2 Changes from baseline in liver enzymes and total
bilirubin in patients receiving pyronaridine-artesunate or
combined comparators (safety population). NB: Day-28 values
are available for the Plasmodium vivax study only [23].
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http://www.malariajournal.com/content/12/1/70group, 0.2% (1/582) of patients had an ALT Grade 4
toxicity on day 3, and for AST 0.5% (3/583) had Grade 3
toxicity on day 3 and 0.2% (1/581) on day 7. Only one
patient in the PA group had a serious adverse event related
to a Grade 3/4 biochemistry value, hepatic enzyme
increased: Grade 3 AST and ALT values on day 7 (295 U/L
and 272 U/L, respectively), decreasing to near normal
levels by day 28 (54 U/L, 25 U/L, respectively); total biliru-
bin was normal at all assessments; ALP was normal except
for a Grade 1 toxicity on day 7 (168 U/L). The proportion
of patients with ALT and/or AST >3x the upper limit of
normal (ULN) plus peak total bilirubin >2xULN in the PA
group was 0.2% (7/2,815) versus 0.3% (2/603) for AL; one
of these patients receiving PA also had a clinically impor-
tant increase in ALP. There were no cases in the MQ+AS
or CQ groups. No clinically important changes were
recorded for urine glucose, protein and blood screening.
The incidence of treatment-emergent clinically im-
portant abnormal electrocardiograph results was 1.1%
(30/2,752) for PA, 0.7% (3/417) for MQ +AS, 0.3% (2/
588) for AL and 2.7% (6/222) for CQ. An adverse event
of QT interval prolongation was recorded for 0.2%
(6/2,815) of patients receiving PA, 1.2% (5/423)
receiving MQ + AS, 0.2% (1/603) receiving AL and
2.6% (6/228) receiving CQ. The proportion of patients
with an adverse event of bradycardia was 1.1% (31/2,815)
for PA and 0.8% (5/603) for AL with no cases in the MQ+
AS or CQ groups. No electrocardiograph abnor-
mality required drug discontinuation or withdrawal
from the study.
Efficacy
Efficacy was evaluated in an integrated analysis of the Phase
III P. falciparum studies SP-C-004-06 [15] SP-C-005-06
[25] and SP-C-007-07 [22]. Day-28 PCR-corrected ACPR
for PA was 93.6% ([1,921/2,052] 95% CI 92.6, 94.7) in the
ITT population and 98.5% ([1,852/1,880] 95% CI 98.0, 99.1)
in the PP population; similar to comparators (Figure 3A).
For day-28 uncorrected ACPR, there was no diffe-
rence between PA and comparators in the ITT or PP
populations (Figure 3B).
Sub-group analysis provided similar day-28 PCR-
corrected ACPR rates (ITT population) regardless of
region, age group, gender, weight, previous malaria,
number of episodes of malaria in the last 12 months, or
baseline parasitaemia (Table 5). There was no difference
in day-28 PCR-corrected ACPR (ITT population)
between the PA granule and tablet formulations: 93.8%
([333/355] 95% CI 91.3, 96.3) and 93.6% ([1,588/1,697]
95% CI 92.4, 94.7), respectively. Efficacy was similar
across the actual PA dose groups: 92.2% ([365/396] 95%
CI 89.5, 94.8) for ≤8.5:2.8 mg/kg/day; 93.9% ([512/545]
95% CI 91.9, 96.0) for >8.5:2.8–9.5:3.2 mg/kg/day; 94.0%



























































































































Figure 3 Day-28 adequate clinical and parasitological response (ACPR): A) PCR-corrected; B) uncorrected. Two-sided 95% confidence
intervals (Wald) were adjusted for study.
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http://www.malariajournal.com/content/12/1/70kg/day; and 93.9% ([428/456] 95% CI 91.6, 96.1) for
>11.0:3.7 mg/kg/day.
Kaplan-Meier estimates of P. falciparum recrudescence
rate and re-infection rate are shown in Figure 4. Both the
recrudescence rate (Figure 4A) and the re-infection rate
(Figure 4B) with PA were intermediate between MQ+AS
and AL.
The majority of patients in all treatment groups had P.
falciparum clearance by day 2 (Table 6). Median parasite
clearance time for P. falciparum (ITT population) was
24.1 h with PA, 31.9 h with MQ +AS, and 24.0 h with
AL (Table 6; Figure 5A). Median parasite clearance time
was extended for all treatments in Asian versus Africancentres (Table 6). In particular, median parasite
clearance time was extended in Cambodia for both
treatment groups at 64.1 h for PA and 64.2 h for
MQ + AS (Figure 5B). In comparison, median para-
site clearance time in Thailand was 31.7 h for PA
and 38.7 h for MQ + AS (Figure 5B). Day-28 PCR-
corrected ACPR (ITT population) in the PA group
in Cambodia was 89.3% (125/140) 95% CI 82.9, 93.9
and in Thailand was 93.3% (375/402) 95% CI 90.4,
95.5. For MQ + AS group, day-28 PCR-corrected
ACPR (ITT population) was 93.0% (66/71) 95% CI 84.3,
97.7 in Cambodia and 88.9% (176/198) 95% CI 83.7, 92.9
in Thailand.
Table 5 Descriptive sub-group analysis of day-28 PCR-corrected ACPR for Plasmodium falciparum (intent-to-treat
population)
Sub-group PA MQ+ AS AL
(n = 2052) (n = 423) (n = 603)
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
Region
Asia 760/829 91.7 (89.8, 93.6) 310/344 90.1 (86.9, 93.3) 64/72 88.9 (81.5, 96.3)
Africa 1161/1223 94.9 (93.7, 96.2) 77/79 97.5 (93.9, 100) 496/531 93.4 (91.3, 95.5)
Age group, years
<5 145/159 91.2 (86.7, 95.6) – – 63/71 88.7 (81.2, 96.3)
5–12 621/656 94.7 (92.9, 96.4) 60/61 98.4 (95.1, 100) 255/274 93.1 (90.0, 96.1)
>12– <18 297/316 94.0 (91.4, 96.6) 52/53 98.1 (94.3, 100) 86/92 93.5 (88.3, 98.6)
≥18 858/921 93.2 (91.5, 94.8) 275/309 89.0 (85.5, 92.5) 156/166 94.0 (90.3, 97.6)
Gender
Male 1213/1301 93.2 (91.9, 94.6) 299/330 90.6 (87.4, 93.8) 293/315 93.0 (90.2, 95.8)
Female 708/751 94.3 (92.6, 95.9) 88/93 94.6 (90.0, 99.3) 267/288 92.7 (89.7, 95.7)
Weight, kg
<17 170/188 90.4 (86.2, 94.7) – – 84/94 89.4 (83.0, 95.7)
17– <25 385/401 96.0 (94.1, 97.9) 38/39 97.4 (92.2, 100) 159/171 93.0 (89.1, 96.8)
≥25 1366/1463 93.4 (92.1, 94.6) 349/384 90.9 (90.9, 93.8) 317/338 93.8 (91.2, 96.4)
Previous malaria
No 828/894 92.6 (90.9, 94.3) 199/220 90.5 (86.5, 94.4) 187/206 90.8 (86.8, 94.8)
Yes 1093/1157 94.5 (93.1, 95.8) 188/203 92.6 (89.0, 96.2) 373/397 94.0 (91.6, 96.3)
Malaria in last 12 months
None 976/1064 91.7 (90.1, 93.4) 232/258 89.9 (86.2, 93.6) 243/269 90.3 (86.8, 93.9)
1 episode 420/444 94.6 (92.5, 96.7) 84/92 91.3 (85.4, 97.2) 111/116 95.7 (92.0, 99.4)
>1 episode 519/537 96.6 (95.1, 98.2) 71/73 97.3 (93.4, 100) 203/215 94.4 (91.3, 97.5)
Baseline parasitaemia, μL-1
≤5000 487/521 93.5 (91.3, 95.6) 102/113 90.3 (84.7, 95.8) 150/161 93.2 (89.2, 97.1)
>5000–10,000 275/293 93.9 (91.1, 96.6) 64/72 88.9 (81.5, 96.3) 78/81 96.3 (92.1, 100)
>10,000 1159/1238 93.6 (92.3, 95.0) 221/238 92.9 (89.6, 96.2) 332/360 92.2 (89.4, 95.0)
–, no data available. PA, pyronaridine-artesunate; MQ + AS, mefloquine plus artesunate; AL, artemether-lumefantrine.
Two-sided confidence intervals (Wald) were adjusted for study.
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http://www.malariajournal.com/content/12/1/70The majority of patients with P. falciparum had fever
clearance by day 1 (Table 6). Median fever clearance
time for P. falciparum in the ITT population was 15.5 h
for PA, 15.8 h for MQ +AS and 14.0 h with AL (Table 6,
Figure 6). Fever clearance times were extended in Asia
versus Africa for all treatments (Table 6).
Plasmodium falciparum gametocytes were present in
8.9% (276/3,078) of patients at baseline, and gradually
decreased to 0% or near 0% in all treatment groups by
the end of the study (Figure 7).
To further investigate P. falciparum gametocyte carriage,
data for the two studies that recruited both adults and
children (SP-C-004-06 and SP-C-005-06) were reanalysed
to calculate the log10 AUC for gametocyte density (Figure 8).
In study SP-C-004-06, in patients who had gametocytes atbaseline, median log10 [AUC gametocyte density] was 3.1
(range 0.1 to 4.4) in the PA group (n = 81) and 2.5 (range
−0.2 to 4.2) in the MQ+AS group (n = 49) (Figure 8A). In
study SP-C-005-06, in patients who had gametocytes at
baseline, median log10 [AUC gametocyte density] was 2.5
(range −0.8 to 4.8) in the PA group (n = 66) and 2.1 (−0.3
to 3.6) in the AL group (n = 22) (Figure 8C). In patients
with no gametocytes at baseline, but who had post-baseline
gametocytes, in study SP-C-004-06, median log10 [AUC
gametocyte density] was 2.1 (range 0.43 to 3.65) in the PA
group (n = 64) and 1.4 (range 0.22 to 3.4) in the MQ+AS
group (n = 17) (Figure 8B). In study SP-C-005-06, median
log10 [AUC gametocyte density] was 0.9 (range −0.5 to 3.0)
in the PA group (n = 67) and 0.5 (−0.5 to 3.2) in the AL
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Figure 4 Plasmodium falciparum A) recrudescence rate B) re-infection rate. Kaplan-Meier survival plot for the integrated efficacy analysis
(intent-to-treat population).
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The integrated safety analysis included 2,815 adults and
children treated with PA for uncomplicated P. falciparum
or P. vivax infection. The PA group was well balanced for
baseline clinical and demographic characteristics with
respect to the combined comparator group. The safety
profile for PA in this analysis was similar to that reported
for pyronaridine and artemisinin monotherapy [21,32-35].
Comparator safety profiles were also consistent with
previous reports for MQ+AS [36-42], AL [25,43-46] and
CQ [23,47,48].
Overall, PA and comparators were generally well
tolerated. Although the nature and incidence of adverse
events were generally similar between PA and comparatorsoverall, dizziness was more common with MQ + AS
(6.6%) and myalgia with CQ (9.2%) than with PA
(1.4% and 3.8%, respectively) (Table 4). Serious adverse
events were uncommon in all treatment groups (0–0.7%).
For PA, only one patient had serious adverse events
thought to be related to drug treatment; hepatic enzymes
increased and incomplete abortion.
The only significant laboratory finding in the PA group
was a mean increase in ALT and AST on days 3 and 7,
compared with decreases in these enzymes for comparators
(Figure 2). As a result of this signal, an Independent Data
Monitoring Committee (IDMC) comprising six members,
including three experts in hepatotoxicity, examined the data
from all of the studies. Increased transaminases have been
Table 6 Plasmodium falciparum parasite and fever clearance times and proportion of patients with clearance on days
1, 2, and 3 (intent-to-treat population)
Outcome PA MQ + AS AL
Parasite clearance
Patients with clearance,% (n/N) 93.7 (1923/2052) 88.2 (373/423) 97.5 (588/603)
Median time to clearance, h 24.1 31.9 24.0
Africa 23.9 23.9 24.0
Asia 32.0 39.2 31.5
Day 1 clearance,% (95% CI) 48.2 (46.2, 50.2) 33.7 (30.8, 36.8) 51.5 (48.5, 54.6)
Day 2 clearance,% (95% CI) 89.9 (88.6, 91.1) 76.1 (72.5, 79.6) 92.0 (90.1, 93.6)
Day 3 clearance,% (95% CI) 94.8 (93.9, 95.6) 84.2 (81.0, 87.1) 96.1 (94.9, 97.2)
Fever clearance
Patients with clearance,% (n/N) 98.0 (1589/1621) 97.8 (348/356) 97.2 (450/463)
Median time to clearance, h 15.5 15.8 14.0
Africa 8.0 8.0 8.0
Asia 16.0 16.0 16.0
Day 1 clearance,% (95% CI) 81.9 (80.1, 83.6) 74.7 (70.8, 78.4) 84.1 (81.2, 86.8)
Day 2 clearance,% (95% CI) 95.8 (94.9, 96.6) 92.2 (89.8, 94.3) 96.7 (95.4, 97.8)
Day 3 clearance,% (95% CI) 97.8 (97.1, 98.3) 95.3 (93.4, 96.8) 98.3 (97.5, 99.0)
PA, pyronaridine-artesunate; MQ + AS, mefloquine plus artesunate; AL, artemether-lumefantrine; NA, not available.
Percentages are based on available observations.
Median percentiles as well as confidence intervals and estimates of survival rates at Day 1, 2 and 3 were adjusted for study.
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studies and two (of four) of the completed Phase I studies.
When they occurred, rises in transaminases peaked by day
7 and levels had normalized or were decreasing by day 28
with no instances of Grade 3 or 4 toxicity at this time point.
Increased transaminases were associated rarely with rises in
total bilirubin, which was often high at baseline and subse-
quently fell during treatment. Overall, 0.2% (7/2,815) of
patients in the PA group and 0.3% (2/603) in the AL group
had ALT and/or AST >3x the upper limit of normal (ULN)
plus peak total bilirubin >2xULN; one of these patients in
the PA group had elevated ALP which precluded them as a
Hy’s law case. Importantly, no patients had any clinical
sequelae related to these liver function changes and as a
result the IDMC concluded that whilst PA treatment is
associated with transient elevated transaminases, the early
onset (day 3–7) and rapid resolution are consistent with a
direct low-level toxicity. Therefore, as PA is dosed for only
three days, the risk of progressive liver injury is small.
Additional studies are ongoing in healthy volunteers and in
patients to assess the hepatic safety profile of PA when the
treatment is administered more than once.
Electrocardiograph results did not suggest any cardiac
safety concerns with PA. As would be expected,
prolonged QT interval was uncommon with PA (0.07%)
but occurred more frequently with the quinoline
derivatives MQ (0.7%) and particularly CQ (2.7%) [49].
Bradycardia was observed as an adverse event in 1.1% ofpatients receiving PA and 0.8% with AL. However, the
finding of bradycardia in a young and otherwise fit
population is likely to be associated with the resolution
of the tachycardia associated with fever as decreases in
mean heart rate were noted across all treatment groups
and have been observed in other studies of anti-malarial
therapy as patients become afebrile and they return to
their normal baseline heart rate [33,50-52].
For the treatment of uncomplicated P. falciparum in
children and adults, there was no difference between PA
and comparators for day-28 PCR-corrected ACPR for
the ITT or PP analyses (Figure 3). This reflects results
from the three P. falciparum Phase III studies in which
non-inferiority of PA day 28 PCR-corrected ACPR (PP
population) was demonstrated versus MQ+AS or AL
[15,22,25]. Sub-group analysis showed similar day-28
PCR-corrected ACPR (ITT population) for PA by region,
age group, gender, weight, previous malaria, malaria in
the last 12 months, and baseline parasitemia versus
efficacy with PA overall (Table 5).
Kaplan-Meier analysis of the integrated efficacy ana-
lysis indicated a P. falciparum recrudescence rate for PA
intermediate between the comparators (Figure 4A).
For individual studies, recrudescence rate over the
42-day study period was marginally higher with PA
versus MQ+AS (P = .049) in SP-C-004-06 and similar
versus AL (P = .90) in SP-C-005-06 and in the paediatric
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Figure 5 Parasite clearance time for A) all centres; B) Cambodia versus Thailand. Kaplan-Meier survival plot for the integrated efficacy
analysis (intent-to-treat population).
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analysis indicated a P. falciparum re-infection rate for
PA intermediate between the comparators (AL highest,
MQ+AS lowest) (Figure 4B). However, in the individual
Phase III studies, re-infection rate was higher with MQ+AS
than PA at day 28 (P = .04), and similar at day 42 (P = .17)
[15]. One difference in the integrated analysis was that
there were more patients in the PA group who where
under 18 years of age than in the MQ+AS group and this
may have increased the re-infection rate for PA relative to
MQ+AS. In support of this, in the Phase III study of PA
versus AL that comprised mostly adults (SP-C-005-06),
PA had a lower re-infection rate than AL (day 28 P = .004,day 42 P = .007) [25], but this difference was not evident
in the paediatric PA versus AL study (SP-C-007-07)
(P = .77) [22]. In the integrated analysis, re-infection
rate was lower with PA than AL and the patients in
the AL group tended to be younger. An alternative
explanation is that there were differences in transmission
rates between the treatment groups given the imbalance
in Asian versus African centres in the integrated analysis.
In the integrated analysis, the P. falciparum parasite
clearance rate was 24.1 h with PA and 32.9 h with MQ
+AS (Figure 5A, Table 6). However, this was not seen in
the comparative Phase III trial of these treatments in
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Figure 6 Fever clearance time. Kaplan-Meier survival plot for the integrated efficacy analysis (intent-to-treat population).
Duparc et al. Malaria Journal 2013, 12:70 Page 14 of 18
http://www.malariajournal.com/content/12/1/7032 h in both arms (P = .08) [15]. This is probably
because of the greater proportion of patients from Africa
in the PA group versus the MQ +AS group in the
integrated analysis; median parasite clearance rates were
longer in Asia than Africa for all comparators (Table 6). In
particular, in Cambodia parasite clearance times were
extended for PA and MQ+AS to around 64 h (Figure 5B).
However, this did not seem to affect the day-28 PCR-
corrected ACPR (ITT population) between Cambodia
and Thailand for either PA or MQ + AS. Extended
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Figure 7 Proportion of patients with Plasmodium falciparum gametoc
Two-sided 95% confidence intervals (Wald) were adjusted for study.artemisinin resistance and the results presented here
are consistent with other reports from the Cambodia–
Thailand border area [8-14,53]. For example, mean parasite
clearance times of around 65 h have been reported for
artemisinin-piperaquine, dihydroartemisinin-piperaquine
and AL in this region [13].
Parasite clearance times were similar between PA and
AL in the integrated analysis (Figure 5A). However, in the
individual studies of PA versus AL, parasite clearance was
faster with PA (P = .02) in study SP-C-007-07 conducted
in children, and in study SP-C-005-06 including mostly64 72 Day 7 Day 14 Day 21 Day 28 Day 35 Day 42
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Figure 8 Plasmodium falciparum gametocyte density over time. A) Study SP-C-004-06 comparing pyronaridine-artesunate to mefloquine +
artesunate gametocyte density over time in patients with baseline gametocytes and B) no gametocytes at baseline and post-baseline
gametocytes. C) Study SP-C-005-06 comparing pyronaridine-artesunate to artemether-lumefantrine gametocyte density over time in patients with
baseline gametocytes and D) no gametocytes at baseline and post-baseline gametocytes. All data are for the intent-to-treat population.
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http://www.malariajournal.com/content/12/1/70adults (P < .001) [22,25]. As above, these differences are
probably explained by the longer parasite clearance times
in Asian versus African centres, there being a relative lack
of patients recruited from Asian centres in the AL group
compared with the PA group in the integrated analysis.
Fever clearance time for PA in the integrated analysis
was approximately intermediate between AL (fastest)
MQ +AS (slowest) (Figure 6). However, in the individual
Phase III studies, fever clearance times were shorter with
PA versus AL in the paediatric study (P = .049) and there
was no difference in the study conducted versus AL
mostly in adults (P = .55) [22,25]. This again probably
reflects the greater proportion of patients recruited from
Asian centres in the PA and MQ +AS groups versus the
AL group in the integrated analysis.
In the integrated analysis, it appeared that AL more
rapidly eradicated gametocytes versus PA and MQ +AS
(Figure 7). However, this is also probably explained by
the difference in baseline populations. To investigate
further, gametocytes carriage was analysed in the two
studies that enrolled both adults and children [15,25],
using log10 AUC [gametocyte density] [54,55]. In patients
with baseline gametocytes, MQ + AS did appear tomore rapidly reduce gametocyte carriage versus PA,
though in patients with no gametocytes at baseline
PA appeared to more effectively suppress gametocyte
emergence (Figure 8). There appeared to be no differences
between AL and PA in respect to gametocyte clearance
or suppression.
Children are the most important target group for anti-
malarial therapy, having reduced immunity and conse-
quently poorer outcomes. Despite this, until recently paedi-
atric ACT formulations have been generally lacking [56].
Paediatric formulations are easier to administer and may be
better tolerated, particularly in terms of vomiting, which
may affect anti-malarial drug levels [57]. A granule formu-
lation was included in the PA development plan to ensure
early availability after drug registration. For the primary effi-
cacy outcome used in the Phase III studies – day-28 PCR-
corrected ACPR – the granule and tablet formulation had
similar efficacy in this analysis. Efficacy outcomes at day 42
were also similar for the two pyronaridine-artesunate
formulations.
For the efficacy analysis, this report is concerned with
the integrated analysis of the PA Phase III P. falciparum
clinical trials. However, the efficacy of PA in P. vivax has
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children [23]. In summary, for the primary outcome –
the day-14 crude cure rate (PP population) – PA efficacy
was 99.5%, (217/218; 95% CI 97.5, 100). This was non-
inferior to CQ 100% efficacy (209/209; 95% CI 98.3,
100); treatment difference −0.5% (95% CI −2.6, 1.4).
Non-inferiority of PA to CQ was maintained throughout
follow-up (days 21, 28, 35 and 42) [23]. Additional
clinical trials will report PA safety and efficacy in young
children with P. vivax malaria and PA efficacy in areas
of chloroquine-resistant P. vivax.
Conclusions
Overall, PA was well tolerated with a similar adverse event
profile to comparators. Although PA was associated with
transient increases in transaminases in a relatively small
proportion of patients, there was no indication of a risk of
progressive liver injury. Pyronaridine-artesunate efficacy
against P. falciparum was consistently high regardless of
geographical region, patient age, gender, or degree of para-
sitaemia. Against P. vivax, PA had efficacy at least as good
as CQ but with more rapid parasite and fever clearance
and a lower parasite re-emergence rate. Importantly, PA
has been developed to have a specific paediatric granule
formulation available, shown to have equivalent pharma-
cokinetics and efficacy to the tablet formulation [24].
Initially, PA will be used in areas of low endemicity and
where cases of artemisinin resistance have been reported
with deployment to areas of high endemicity once
further data on repeated treatment with PA have been
obtained. Pyronaridine-artesunate is a useful new
ACT and should be a valuable addition to anti-malarial
treatment programmes.
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